In this study, we mapped the cerebral expression of Fos protein following intrastriatal stimulation of D1 or D2 receptors, in freely moving animals. Animals treated with the D1 agonist SKF 38393 showed massive Fos increases in the cerebral cortex, ipsilaterally to the injected striatum, which were counteracted by systemic administration of D1 antagonist SCH 23390. Conversely, D2 agonist quinpirole suppressed cortical expression of Fos, while systemic administration of D2 antagonist eticlopride relieved this blockade. As for the basal ganglia, Fos was consistently expressed only in the injected striatum of rats receiving SKF 38393. These results show that striatal dopamine receptors may play a role in the modulation of cortical activity. They also provide new information on a class of drugs - the dopamine agonists - whose role in the therapeutic strategy of Parkinson's disease is continuously evolving.
ASJC Scopus subject areas
- Clinical Neurology